BDRX (Biodexa Pharmaceuticals) Dividends Paid

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDRX Biodexa Pharmaceuticals PLC BDRX
24 GF Score
Price $0.66
GF Value $0.70
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Biodexa Pharmaceuticals Dividends Paid?

Dividends Paid only applicable to companies reporting Cash Flow from Operations in direct method.

BDRX
24GF Score
Biodexa Pharmaceuticals PLC BDRX
Dividends Paid is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be undervalued. The current stock price of $0.66 is trading 5.7% below its estimated GF Value™ of $0.70. GuruFocus considers Biodexa Pharmaceuticals to be Fairly Valued.

Key valuation signals for BDRX:

  • Dividends Paid:
  • GF Value™: $0.70 vs. price of $0.66 (5.7% below fair value)
  • GF Score™: 24/100 with 1 warning sign

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
24GF Score

Get the complete analysis for BDRX

Dividends Paid is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.66
Price
$0.70
GF Value